T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 1058–1066 (1999). Article CAS PubMed Google Scholar Schmidt, B. et al. A natural history of botanical therapeutics. Metabolism 57, S3–S9 (2008). Article...
Stock Investing News, Analysis and Tips Sep 5, 2023 7:00 AM EDT Is Walgreens so bad it's a buy? Shares slumped on Friday after the company and its CEO agreed to part ways. The pharmacy giant faces huge challenges. Yes, the stock is cheap, but letting it settle first may be a good...
T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 1058–1066 (1999). Article CAS PubMed Google Scholar Schmidt, B. et al. A natural history of botanical therapeutics. Metabolism 57, S3–S9 (2008). Article...
Breakthroughs in therapies for NASH and remaining challenges 2022, Journal of Hepatology Show abstract Physiological and pathological roles of lipogenesis 2023, Nature Metabolism Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) 2023, Frontiers in Endocrinology Targeted therapeutics ...
While there are added challenges associated with building bioplatforms, we believe the advantages and outsized potential returns far outweigh the risks. Why are bioplatforms an attractive investment? Let’s look at the simplest possible example. If you were to invest in a singl...
Figure 3. The process of nanomedicine from discovery to clinical adoption. In this review, we highlight recent clinical advancements in cancer nanomedicine and explore key challenges, case studies, and emerging opportunities in the field. Throughout the review, we provide perspective on how we can...
Gene knockdown via RNA interference can be induced by small interfering RNAs and opens novel avenues towards innovative therapies in many diseases. Despite their very attractive mechanism of action, the development of small interfering RNA therapeutics faces several challenges and issues. ...
Levin, Verdine and Jonas each acknowledged the challenges that lay ahead. But they also argued turbulent times can bring positive changes to the industry, as they’ve done in the past. “We’re in a really great period of innovation,” Jonas said. “So I have a lot of faith … that ...
Breakthroughs like DNA delivery for approved gene therapies and RNA delivery for silencing of genes (patisiran, ONPATTRO®, Alnylam Pharmaceuticals, Cambridge, MA, USA) or for vaccination such as the RNA-based coronavirus disease 2019 (COVID-19) vaccines demonstrated the feasibility of using ...
drugs for primary health care. They were commercially attractive but only modestly innovative. The bigger companies have found it harder to ride more recent waves of scientific research, which have centred on so-called ?large molecules? such as proteins and the breakthroughs yielded by the science...